CYP2J2/ω-3 DHA epoxides (sEH inhibition) · lipidomics · -
Composite 0.725
Price $0.72
Evidence For 0
Evidence Against 0
ω-3 Docosahexaenoic Acid (DHA) Epoxide Generation via CYP2J2 to Protect Synaptic Membranes from Aβ-Induced Rigidification
Convergent vs Divergent Predictions
This summary checks where the selected hypotheses point toward the same target or mechanism, and where they pull in opposite directions.
Unspecified Mechanismlipidomics
Convergent signals
No same-target convergence detected in this selection.
Divergent signals
No direct polarity conflicts detected among the selected hypotheses.
Verdict Summary
3/11
dimensions won
GM1 Ganglioside Reduction via ST3GAL5 Ac
9/11
dimensions won
ω-3 Docosahexaenoic Acid (DHA) Epoxide G
Radar Chart — 10 Dimensions
Score Comparison Bars
Mechanistic
0.45
0.80
Evidence
0.50
0.75
Novelty
0.75
0.60
Feasibility
0.25
0.75
Impact
0.50
0.80
Druggability
0.20
0.80
Safety
0.35
0.70
Competition
0.80
0.55
Data
0.40
0.75
Reproducible
0.45
0.75
KG Connect
0.50
0.50
Score Breakdown
Dimension
GM1 Ganglioside Reduction via
ω-3 Docosahexaenoic Acid (DHA)
Mechanistic
0.450
0.800
Evidence
0.500
0.750
Novelty
0.750
0.600
Feasibility
0.250
0.750
Impact
0.500
0.800
Druggability
0.200
0.800
Safety
0.350
0.700
Competition
0.800
0.550
Data
0.400
0.750
Reproducible
0.450
0.750
KG Connect
0.500
0.500
Evidence
GM1 Ganglioside Reduction via ST3GAL5 Activation to Block Aβ
No evidence citations yet
ω-3 Docosahexaenoic Acid (DHA) Epoxide Generation via CYP2J2
No evidence citations yet
Debate Excerpts
GM1 Ganglioside Reduction via ST3GAL5 Activation t
4 rounds · quality: 0.50
Theorist
# Novel Therapeutic Hypotheses: Lipid Metabolism Dysregulation in Alzheimer's Disease
---
## Hypothesis 1: CYP46A1 Activation as a Therapeutic Strategy to Restore Neuronal Cholesterol Efflux and R...
Skeptic
# Critical Evaluation of Lipid Metabolism Hypotheses in Alzheimer's Disease
## Hypothesis 1: CYP46A1 Activation
### Weaknesses in Evidence
The hypothesis presents a linear model of cholesterol ef...
Domain Expert
# Drug Development Assessment: Lipid Metabolism Hypotheses in Alzheimer's Disease
## Executive Summary
The seven hypotheses span a spectrum of druggability—from well-established nuclear receptor a...
# Novel Therapeutic Hypotheses: Lipid Metabolism Dysregulation in Alzheimer's Disease
---
## Hypothesis 1: CYP46A1 Activation as a Therapeutic Strategy to Restore Neuronal Cholesterol Efflux and R...
Skeptic
# Critical Evaluation of Lipid Metabolism Hypotheses in Alzheimer's Disease
## Hypothesis 1: CYP46A1 Activation
### Weaknesses in Evidence
The hypothesis presents a linear model of cholesterol ef...
Domain Expert
# Drug Development Assessment: Lipid Metabolism Hypotheses in Alzheimer's Disease
## Executive Summary
The seven hypotheses span a spectrum of druggability—from well-established nuclear receptor a...